Skip to Main Content

Charles Lockwood, MD

Professor (Adjunct) of Obstetrics, Gynecology, and Reproductive Sciences

Contact Information

Charles Lockwood, MD

Research Summary

Trophoblast, Placenta, Labor Premature, Fetal Diseases, Pregnancy Complications, Pregnancy, Endometrium, Fibronectins, Plasminogen Activators, Plasminogen Inactivators, Annexins, Proteins, Fetal Membranes, EmbryoMy research is devoted to understanding the basic mechanisms underlying the maintenance of normal hemostasis during blastocyst invasion and the establishment of the uteroplacental circulation as well as those mechanisms involved int he pathologic outcomes associated with these processes.

We are also investigating the pathophysiology of abnormal uterine bleeding (AUB) associated with the perimenarchal and perimenopausal periods, anovulation, myomas, polyps, carcinomas and long-term progestin-only contraceptive therapy. A future goal involves the early identification of individuals predisposed to these pathologies in order to prevent preterm labor, abruptions and abnormal uterine bleeding by therapies that block the pathways leading to these events.

Extensive Research Description

Dr. Lockwood is the Anita O'Keefe Young Professor of Women’s Health and Chair, Department of Obstetrics Gynecology and Reproductive Sciences, Yale University School of Medicine. His clinical interests include: recurrent pregnancy loss, prematurity prevention, multi-fetal pregnancies, maternal thrombophilias and thrombosis, and prenatal diagnosis. His clinical research interests include uncovering genetic predispositions to prematurity and fetal growth restriction. His translational research is devoted to understanding the basic mechanisms underlying the maintenance of hemostasis during blastocyst invasion and the establishment of the uteroplacental circulation as well as the causes of placental abruption and abruption-related preterm delivery.

His lab has also focused on the pathophysiology of abnormal uterine bleeding (AUB) associated with the idiopathic menorrhagia, anovulation, myomas, endometrial polyps and long-term progestin-only contraceptive therapy. Of key interest to these studies is the identification of pathways which may lead to aberrant angiogenesis. Recently he has examined aberrant tissue factor expression in endometriotic endothelium as a target for therapy using the immunoconjugate molecule, ICON. He has over 220 peer reviewed publications, 39 chapters in distinguished text books, is editor of four text books, UpToDate - Obstetrics and Contemporary Ob/Gyn, the nation’s must widely read Ob/Gyn journal. He serves on the editorial board of several journals and is a former President of the the Society for Gynecologic Investigation
  • Citations: 5983
  • Citations/year: 426
  • Average citations/paper: 22.7
  • H-index: 40

Targeting tissue factor expression in endometriosis and endometrial cancer with an immunoconjugate molecule.

Uncovering the causes of abnormal uterine bleeding in patients receiving long-term progestin-only contraceptives.

Dissecting the mechanisms for progesterone receptor withdrawal in infection and abruption-associated preterm deliveries.

Uncovering the control of leukocyte traffiking in the placental bed and the role of decidual macrophages in impairning endovascular extravillous trophoblast invasion.

Coauthors

Selected Publications